Is SNTI.OB a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

244 people get SNTI.OB articles and Market Currents by email alert.

Get email alerts on SNTI.OB »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Is Senesco Technologies The Next Cellceutix?
Markus Aarnio • Thu, Feb 7 • 55 Comments

To learn more about Seeking Alpha Pro, click here.

5 Stocks That Give You Biologic Solutions
Dutch Trader • Sun, Feb 24 • 9 Comments
Multiple Myeloma And Different Treatment Approaches
Carl Cachia • Sun, Feb 17 • 9 Comments
3 Companies Trying To Beat Cancer
Devon Shire • Fri, Feb 8 • 9 Comments
Small-Pharma Watch List: Week Of January 28th
Chemistfrog • Mon, Jan 28 • 11 Comments
Gene Therapy: Which Companies To Invest In?
Dutch Trader • Mon, Jan 28 • 10 Comments
4 Promising Growth Stories In Therapeutics
Cris Frangold • Fri, Jan 18 • 4 Comments
Investing In The Future Of Multiple Myeloma Treatment
Brian L. Wilson • Wed, Jan 16 • 10 Comments
Analyzing Last Week's Noteworthy Insider Buys And Sells In Healthcare Sector
GuruFundPicks • Mon, Jan 23, 2012

There are no Transcripts on SNTI.OB.

Senesco Technologies Reports Second Quarter Fiscal 2013 Financial Results

Business Wire (May 16, 2013)
Senesco Announces Presentation on Combination Therapy with Novel Nanoparticle, SNS01-T, and Bortezomib Results in Synergistic Cytotoxicity In Vitro and In Vivo in Multiple Myeloma

Business Wire (May 14, 2013)
Senesco Announces $1.255 Million Equity Financing

Business Wire (May 9, 2013)
Senesco Announces Start of Cohort 3 in Phase 1b/2a Study in Multiple Myeloma and Non-Hodgkins B-Cell Lymphoma

Business Wire (May 6, 2013)
Senesco Announces Completion of Cohort 2 of its Phase 1b/2a Trial

Business Wire (Apr 22, 2013)
Senesco Provides Management Update

Business Wire (Apr 8, 2013)
Senesco Technologies Provides Corporate Update

Business Wire (Mar 5, 2013)
Senesco Technologies Reports Second Quarter Fiscal 2013 Financial Results

Business Wire (Feb 15, 2013)
Senesco Announces Quotation of Common Stock on the Over-the-Counter Securities Market

Business Wire (Nov 21, 2012)
Senesco Announces Delisting of Common Stock from NYSE MKT LLC and Pending Transfer to an Over-the-Counter Securities Market

Business Wire (Nov 19, 2012)
Senesco Technologies Reports First Quarter Fiscal 2013 Financial Results

Business Wire (Nov 15, 2012)
Senesco Announces Expansion of Phase 1b/2a Study to Include Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

Business Wire (Nov 7, 2012)
Senesco Technologies Reports Fiscal Year 2012 Financial Results

Business Wire (Sep 18, 2012)
Senesco Announces First Dose of SNS01-T in Cohort 2 of Phase 1b/2a Study in Multiple Myeloma Trial

Business Wire (Sep 13, 2012)
Combining SNS01-T with Bortezomib Significantly Increases Its Effectiveness in Model of Multiple Myeloma

Business Wire (Sep 10, 2012)
Senesco to Present at Rodman & Renshaw Annual Global Investment Conference

Business Wire (Sep 5, 2012)
Senesco Technologies Receives Notice of Non-Compliance from NYSE MKT

Business Wire (Aug 27, 2012)
Senesco Announces that SNS01-T Showed Good Tolerability and Stable Disease in Newly Completed First Cohort of Phase 1b/2a Multiple Myeloma Trial

Business Wire (Aug 15, 2012)
Senesco Announces Highly Statistically Significant Tumor Growth Inhibition by a Combination of Lenalidomide and SNS01-T in Cancer Model

Business Wire (Aug 13, 2012)
Senesco’s Lead Therapeutic Candidate, SNS01-T, Granted Orphan Drug Status from FDA for Treatment of Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Business Wire (Jul 30, 2012)

SNTI.OB vs. ETF Alternatives

Company Description

Currently, there's no company description for SNTI.OB.

Sector: Healthcare

Industry: Biotechnology

Country: United States

SNTI.OB Senesco Technologies, Inc

SNTI.OB

Senesco Technologies, Inc